Directing treatments for glioblastoma based on identifying a somatic structural rearrangement upstream from TERT gene
AssigneeDuke University
InventorsHai Yan, Bill H. Diplas
Life of this patent
Estimating the term…
Loading patent…
AssigneeDuke University
InventorsHai Yan, Bill H. Diplas
Estimating the term…
The majority of glioblastomas can be classified into molecular subgroups based on mutations in the TERT promoter (TERTp) and isocitrate dehydrogenase 1 or 2 (IDH). These molecular subgroups utilize distinct genetic mechanisms of telomere maintenance, either TERTp mutation leading to telomerase activation or ATRX-mutation leading to an alternative lengthening of telomeres phenotype (ALT). However, about 20% of glioblastomas lack alterations in TERTp and IDH. These tumors, designated TERTpWT-IDHWT glioblastomas, did not have well-established genetic biomarkers or defined mechanisms of telomere maintenance. The genetic landscape of TERTpWT-IDHWT glioblastoma includes tumors that have chromosomal rearrangements upstream of TERT. These rearrangements define a novel molecular subgroup of glioblastoma, that is a telomerase-positive subgroup driven by TERT-structural rearrangements (IDHWT-TERTSV).
A method of treating a glioma tumor of a human comprising:
A method of treating a glioma tumor of a human comprising:
Dependencies are inferred from the claim text.